UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Globus Medical Inc (GMED)

Globus Medical Inc (GMED)
83.00 x 1 84.50 x 1
Post-market by (Cboe BZX)
83.93 -0.20 (-0.24%) 02/14/25 [NYSE]
83.00 x 1 84.50 x 1
Post-market 83.93 unch (unch) 16:00 ET
Quote Overview for Fri, Feb 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
83.87
Day High
84.84
Open 84.42
Previous Close 84.13 84.13
Volume 671,700 671,700
Avg Vol 1,217,245 1,217,245
Stochastic %K 7.67% 7.67%
Weighted Alpha +47.46 +47.46
5-Day Change -3.69 (-4.21%) -3.69 (-4.21%)
52-Week Range 49.33 - 94.93 49.33 - 94.93
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,428,498
  • Shares Outstanding, K 136,167
  • Annual Sales, $ 1,568 M
  • Annual Income, $ 122,870 K
  • EBIT $ 233 M
  • EBITDA $ 459 M
  • 60-Month Beta 1.19
  • Price/Sales 4.61
  • Price/Cash Flow 23.32
  • Price/Book 2.81

Options Overview Details

View History
  • Implied Volatility 41.91% ( +1.58%)
  • Historical Volatility 24.76%
  • IV Percentile 96%
  • IV Rank 76.05%
  • IV High 49.38% on 08/05/24
  • IV Low 18.22% on 11/26/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 152
  • Volume Avg (30-Day) 664
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 11,512
  • Open Int (30-Day) 9,015

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.76
  • Number of Estimates 8
  • High Estimate 0.87
  • Low Estimate 0.70
  • Prior Year 0.60
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.07 +1.04%
on 02/13/25
Period Open: 88.18
94.93 -11.59%
on 01/30/25
-4.25 (-4.82%)
since 01/14/25
3-Month
80.59 +4.14%
on 11/15/24
Period Open: 81.10
94.93 -11.59%
on 01/30/25
+2.83 (+3.49%)
since 11/14/24
52-Week
49.33 +70.14%
on 05/01/24
Period Open: 52.75
94.93 -11.59%
on 01/30/25
+31.18 (+59.11%)
since 02/14/24

Most Recent Stories

More News
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

GMED : 83.93 (-0.24%)
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

GMED : 83.93 (-0.24%)
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

GMED : 83.93 (-0.24%)
3 MedTech Stocks to Grab Now for a Strong 2025

This article highlights three MedTech stocks poised for growth in 2025

SYK : 385.18 (-0.82%)
GMED : 83.93 (-0.24%)
ISRG : 595.55 (+0.70%)
Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls

The Cooper Companies, Inc. COO delivered fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.04, which improved 19.5% year over year. The figure surpassed the Zacks Consensus Estimate by...

COO : 88.10 (-5.96%)
GMED : 83.93 (-0.24%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
Insider Sale: SVP of $GMED (GMED) Sells 2,500 Shares

Kelly Huller, the SVP of $GMED ($GMED), sold 2,500 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares....

GMED : 83.93 (-0.24%)
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care

GE HealthCare Technologies Inc. GEHC announced its collaboration with Melbourne, Australia-based Peter MacCallum Cancer Centre on Monday. The tie-up will enable GEHC to further develop and explore the...

GMED : 83.93 (-0.24%)
COR : 242.63 (-0.55%)
GEHC : 92.21 (-1.36%)
CAH : 126.21 (-0.45%)
Insider Sale: President of $GMED (GMED) Sells 130,000 Shares

Daniel T Scavilla, the President of $GMED ($GMED), sold 130,000 shares of the company on 11-21-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their...

GMED : 83.93 (-0.24%)
Globus Medical, Inc. Announces Commercial Launch of ExcelsiusHubâ„¢ Navigation System for Spine Surgery

Globus Medical launches ExcelsiusHubâ„¢ navigation system, enhancing spinal surgery with improved accuracy and reduced radiation exposure.Quiver AI SummaryGlobus Medical, Inc. has announced the commercial...

GMED : 83.93 (-0.24%)
Globus Medical Launches ExcelsiusHubâ„¢ Navigation System

GMED : 83.93 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices,...

See More

Key Turning Points

3rd Resistance Point 85.53
2nd Resistance Point 85.18
1st Resistance Point 84.56
Last Price 83.93
1st Support Level 83.59
2nd Support Level 83.24
3rd Support Level 82.62

See More

52-Week High 94.93
Last Price 83.93
Fibonacci 61.8% 77.51
Fibonacci 50% 72.13
Fibonacci 38.2% 66.75
52-Week Low 49.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion